专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5821106A CDNA of direct-acting fibrinolytic serine protease 失效
标题翻译：直接作用的纤维蛋白溶解丝氨酸蛋白酶的CDNA
公开(公告)号：US5821106A
公开(公告)日：1998-10-13
申请号：US738413
申请日：1996-10-25
申请人： Kwang-Hoe Chung , You-Seok Koh , Jae-Hoon Hwang , Doo-Sik Kim , Yung-Dae Yun , Hong-Mo Moon
发明人： Kwang-Hoe Chung , You-Seok Koh , Jae-Hoon Hwang , Doo-Sik Kim , Yung-Dae Yun , Hong-Mo Moon
IPC分类号： C12N15/09 , A61K38/00 , A61K38/48 , A61P7/02 , C07H21/04 , C12N9/50 , C12N9/64 , C12N15/55 , C12N15/57 , C12R1/91
CPC分类号： C12N9/6418 , A61K38/00
摘要： The present invention relates to a novel cDNA of direct-acting fibrinolytic serine protease ("Salmonase") which is prepared from a Korean viper, Salmosa(Agkistrodon halys brevicaudus), and a direct-acting fibrinolytic serine protease deduced therefrom. The cDNA of direct-acting fibrinolytic serine protease contains 699 nucleotides coding for 233 amino acids, and the Salmonase translated therefrom consists of two subunits of 77 and 156 amino acids, respectively. Salmonase cDNA of the invention may be expressed in the proper systems established in the recombinant E. coli, yeast, baculovirus/insect cells and other animal cells, and the recombinant Salmonase prepared therefrom can be practically applied as an active ingredient of thrombolytic and hemostatic agents.
摘要翻译：本发明涉及由韩国蛇蝎（Salmosa）（枸杞子）和由其推断的直接作用的纤维蛋白溶解丝氨酸蛋白酶制备的直接作用的纤维蛋白溶解丝氨酸蛋白酶（“Salmonase”）的新型cDNA。直接作用的纤维蛋白溶解丝氨酸蛋白酶的cDNA含有编码233个氨基酸的699个核苷酸，转录的Salmonase分别由77个和156个氨基酸的两个亚基组成。本发明的Salmonase cDNA可以在重组大肠杆菌，酵母，杆状病毒/昆虫细胞和其他动物细胞中建立的适当系统中表达，并且由此制备的重组Salmonase可以实际应用为溶栓和止血剂的活性成分。

2. 发明授权

US5889148A Antibiotic peptides 失效
标题翻译：抗生素肽
公开(公告)号：US5889148A
公开(公告)日：1999-03-30
申请号：US700449
申请日：1996-08-27
申请人： Keun-Hyeung Lee , Sung-Yu Hong , Hyun-Sook Cho , Bok-Leul Lee , Kwang-Hoe Chung , Jeong-Hyeok Yoon , Jong-Eun Oh , Hong-Mo Moon
发明人： Keun-Hyeung Lee , Sung-Yu Hong , Hyun-Sook Cho , Bok-Leul Lee , Kwang-Hoe Chung , Jeong-Hyeok Yoon , Jong-Eun Oh , Hong-Mo Moon
IPC分类号： A61K38/00 , A61P31/04 , C07K14/435 , C07K5/00 , C07K7/00 , C07K15/00
CPC分类号： C07K14/43563 , A61K38/00
摘要： The present invention relates to novel antibiotic peptides which possess antibacterial and/or antifungal activities causing no cytotoxicity, and to antibacterial and/or antifungal agents containing said peptides as active ingredients. In accordance with the present invention, it has been discovered that a number of chemically-synthesized peptides which are derived from Tenecin, show superior antibacterial and/or antifungal activities, while causing no untoward effects, and they can be applied for the development of antibacterial and/or antifungal agents.
摘要翻译： PCT No.PCT / KR96 / 00034 Sec。 371日期：1996年8月27日 102（e）日期1996年8月27日PCT 1996年3月11日PCT公布。出版物WO97 / 02286 日期1997年1月23日本发明涉及具有不引起细胞毒性的抗细菌和/或抗真菌活性的新型抗生素肽以及含有所述肽作为活性成分的抗细菌剂和/或抗真菌剂。根据本发明，已经发现，从Tenecin衍生的多种化学合成的肽显示出优异的抗菌和/或抗真菌活性，同时不会产生不利影响，并且它们可用于开发抗菌剂和/或抗真菌剂。

3. 发明授权

US5985609A Process for preparing hepatitis C virus envelope glycoproteins 失效
标题翻译：制备丙型肝炎病毒包膜糖蛋白的方法
公开(公告)号：US5985609A
公开(公告)日：1999-11-16
申请号：US334545
申请日：1994-11-04
申请人： Mi-Kyung Min , Joon-Sang Park , Jung-Seob Kim , Yung-Dae Yun , Hong-Mo Moon
发明人： Mi-Kyung Min , Joon-Sang Park , Jung-Seob Kim , Yung-Dae Yun , Hong-Mo Moon
IPC分类号： A61K39/00 , C07K14/18 , C12N15/51 , C07H21/04 , C12Q1/70
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222
摘要： The present invention relates to a novel process for preparing hepatitis C virus (HCV) envelope glycoproteins employing Chinese Hamster Ovary (CHO) cells transformed with recombinant expression vectors containing the hepatitis C virus genome. The present invention provides CHO cells cotransfected with DHFR (dihydrofolate reductase) minigene pDCHIP and recombinant expression vectors containing cDNAs of HCV E1 and E2/NS1 ligated with tissue plasminogen activator signal sequence. HCV E1 and E2/NS1 envelope glycoproteins are produced in a massive manner from the transformed CHO cells adapted in methotrexate. The HCV envelope glycoproteins produced by the present invention can be applied to the development of a diagnostic reagent and a potential preventive HCV vaccine.
摘要翻译：本发明涉及使用含有丙型肝炎病毒基因组的重组表达载体转化的中国仓鼠卵巢（CHO）细胞制备丙型肝炎病毒（HCV）包膜糖蛋白的新方法。本发明提供了与DHFR（二氢叶酸还原酶）小基因pDCHIP共转染的CHO细胞和含有与组织纤溶酶原激活物信号序列连接的HCV E1和E2 / NS1的cDNA的重组表达载体。从适应于甲氨蝶呤的转化的CHO细胞以大量方式产生HCV E1和E2 / NS1包膜糖蛋白。由本发明生产的HCV包膜糖蛋白可用于开发诊断试剂和潜在的预防性HCV疫苗。

4. 发明授权

US5635473A Inhibitor of hepatitis B virus replication 失效
标题翻译：乙型肝炎病毒复制抑制剂
公开(公告)号：US5635473A
公开(公告)日：1997-06-03
申请号：US347343
申请日：1995-04-24
申请人： Hyun-Sook Lee , Yung-Dae Yun , Hong-Mo Moon
发明人： Hyun-Sook Lee , Yung-Dae Yun , Hong-Mo Moon
IPC分类号： A61K38/02 , A61K38/00 , C07K14/47 , C07K14/82
CPC分类号： C07K14/4746 , A61K38/00
摘要： The present invention relates to a novel use of a biologically active protein, p53 as an inhibitor of hepatitis B virus(HBV) replication. The inhibitory role of p53 on HBV replication was assessed by the reduced levels of three different markers, i.e., HBsAg and HBc/eAg secreted into the medium, HBV DNA, and RNAs. Based on the above results, it was concluded that wild-type p53 specifically represses the activity of pregenomic/core promoter of HBV and inhibits the replication of HBV by down-regulation of the pregenomic/core promoter. Therefore, the present invention provides a novel use of protein p53 as a HBV replication inhibitor which can be developed into an agent for the treatment of acute/chronic hapatitis and prevention of liver cirrhosis and hepatocellular carcinoma(HCC) caused by HBV.
摘要翻译： PCT No.PCT / KR94 / 00136 Sec。 371日期1995年04月24日 102（e）日期1995年4月24日PCT 1994年10月12日PCT PCT。公开号WO96 / 11017 日期1996年04月18日本发明涉及生物活性蛋白质p53作为乙型肝炎病毒（HBV）复制抑制剂的新用途。通过三种不同标志物的水平降低，即分泌到培养基中的HBsAg和HBc / eAg，HBV DNA和RNA来评估p53对HBV复制的抑制作用。基于上述结果，得出结论，野生型p53特异性抑制HBV的前基因组/核心启动子的活性，并通过下调前基因组/核心启动子来抑制HBV的复制。因此，本发明提供蛋白质p53作为HBV复制抑制剂的新用途，其可以发展成用于治疗急性/慢性单性疱疹的药物和由HBV引起的肝硬化和肝细胞癌（HCC）的预防。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式